330 related articles for article (PubMed ID: 22045709)
1. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent.
Gourni E; Demmer O; Schottelius M; D'Alessandria C; Schulz S; Dijkgraaf I; Schumacher U; Schwaiger M; Kessler H; Wester HJ
J Nucl Med; 2011 Nov; 52(11):1803-10. PubMed ID: 22045709
[TBL] [Abstract][Full Text] [Related]
2. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4.
Yang T; Shi D; Lin Q; Shen H; Tan H; Liu Y; Shi H; Cheng D
Mol Pharm; 2024 May; 21(5):2415-2424. PubMed ID: 38606663
[TBL] [Abstract][Full Text] [Related]
4. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET.
Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F
Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818
[TBL] [Abstract][Full Text] [Related]
5. [
Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
[TBL] [Abstract][Full Text] [Related]
6. [
Konrad M; Rinscheid A; Wienand G; Nittbaur B; Wester HJ; Janzen T; Lapa C; Pfob CH; Schottelius M
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3937-3948. PubMed ID: 37597009
[TBL] [Abstract][Full Text] [Related]
7. Validation of [
Schottelius M; Ludescher M; Richter F; Kapp TG; Kessler H; Wester HJ
EJNMMI Res; 2019 Aug; 9(1):75. PubMed ID: 31410585
[TBL] [Abstract][Full Text] [Related]
8. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
[TBL] [Abstract][Full Text] [Related]
9. High-Contrast CXCR4-Targeted
Kwon D; Lozada J; Zhang Z; Zeisler J; Poon R; Zhang C; Roxin Á; Lin KS; Perrin D; Benard F
Mol Pharm; 2021 Jan; 18(1):187-197. PubMed ID: 33253591
[TBL] [Abstract][Full Text] [Related]
10. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
[TBL] [Abstract][Full Text] [Related]
11. In vivo validation of
Renard I; Domarkas J; Poty S; Burke BP; Roberts DP; Goze C; Denat F; Cawthorne CJ; Archibald SJ
Nucl Med Biol; 2023; 120-121():108335. PubMed ID: 37068392
[TBL] [Abstract][Full Text] [Related]
12. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.
Wester HJ; Keller U; Schottelius M; Beer A; Philipp-Abbrederis K; Hoffmann F; Šimeček J; Gerngross C; Lassmann M; Herrmann K; Pellegata N; Rudelius M; Kessler H; Schwaiger M
Theranostics; 2015; 5(6):618-30. PubMed ID: 25825601
[TBL] [Abstract][Full Text] [Related]
13. Comparative studies of three 68Ga-labeled [Des-Arg10]kallidin derivatives for imaging bradykinin B1 receptor expression with PET.
Lin KS; Amouroux G; Pan J; Zhang Z; Jenni S; Lau J; Liu Z; Hundal-Jabal N; Colpo N; Bénard F
J Nucl Med; 2015 Apr; 56(4):622-7. PubMed ID: 25745086
[TBL] [Abstract][Full Text] [Related]
14. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
15. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
Lopez-Rodriguez V; Gaspar-Carcamo RE; Pedraza-Lopez M; Rojas-Calderon EL; Arteaga de Murphy C; Ferro-Flores G; Avila-Rodriguez MA
Nucl Med Biol; 2015 Feb; 42(2):109-14. PubMed ID: 25316595
[TBL] [Abstract][Full Text] [Related]
16. First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers.
Vag T; Gerngross C; Herhaus P; Eiber M; Philipp-Abbrederis K; Graner FP; Ettl J; Keller U; Wester HJ; Schwaiger M
J Nucl Med; 2016 May; 57(5):741-6. PubMed ID: 26769866
[TBL] [Abstract][Full Text] [Related]
17. Second generation Al
Spahn MA; Luyten K; Van Loy T; Sathekge M; Deroose CM; Koole M; Schols D; Vanduffel W; De Vos K; Annaert P; Bormans G; Cleeren F
Nucl Med Biol; 2024; 132-133():108906. PubMed ID: 38518400
[TBL] [Abstract][Full Text] [Related]
18. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
19. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
[TBL] [Abstract][Full Text] [Related]
20. In Vivo PET Imaging of the Cancer Integrin αvβ6 Using
Notni J; Reich D; Maltsev OV; Kapp TG; Steiger K; Hoffmann F; Esposito I; Weichert W; Kessler H; Wester HJ
J Nucl Med; 2017 Apr; 58(4):671-677. PubMed ID: 27980050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
